Sponsor of the Day:
Jerkmate
https://www.sanofi.com/en/media-room/press-releases/2026/2026-03-24-06-00-00-3260948
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to...
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe...
press release sanofidupixent approvedfirst targetedjapanmedicine
https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-27-12-03-24-3246438
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic...
Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If...
press release sanofieu approvaltreat chronicdupixentrecommended
https://www.pharmexec.com/view/fda-expands-approval-dupixent-young-children-uncontrolled-chronic-spontaneous-urticaria
FDA Expands Approval for Dupixent for Young Children with Uncontrolled Chronic Spontaneous...
Apr 24, 2026 - FDA expands Dupixent approval to children aged 2–11 with chronic spontaneous urticaria, marking the first biologic option for this population and extending its...
young childrenchronic spontaneousfdaexpandsapproval
https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-24-14-30-00-3243732
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine...
Sanofi and Regeneron s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6...
press release sanofidupixent approvedusfirstmedicine
https://www.classaction.org/dupixent-lymphoma-lawsuits
Dupixent Lawsuits: Cutaneous T Cell Lymphoma & Cancer Risk | Legal Info
Feb 4, 2026 - Learn more about Dupixent cancer lawsuits, including who qualifies, what’s involved in taking action and what you could recover in a successful case.
cell lymphomacancer risklegal infodupixentlawsuits
https://chaffinluhana.com/practice-area/personal-health-and-dangerous-products/dangerous-drugs/dupixent-lymphoma-lawsuit/
Dupixent Lymphoma Lawsuit | Chaffin Luhana LLP Personal Injury Lawyers
Worried Dupixent led to lymphoma? Learn if you may qualify for a Dupixent lymphoma lawsuit and talk with Chaffin Luhana about your legal options.
chaffin luhana llppersonal injury lawyersdupixentlymphomalawsuit
https://www.brandsharestudio.com/case-study-dupixent
Case Study - Dupixent — BrandStudio
case studydupixentbrandstudio
https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-13-05-00-00-3272182
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to...
Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Approval in CSU...
press release sanofidupixent approvedfirst targetedeumedicine